Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001755569 XXXXXXXX LIVE 2 Common Stock, Par Value $0.001 08/19/2025 false 0001094038 57055L107 Marker Therapeutics, Inc. 2450 HOLCOMBE BLVD TMC PARTNERS OFFICE 1.311 HOUSTON TX 77021 John R. Wilson 651-628-9259 2100 Old Highway 8 NW St. Paul MN 55112 0001755569 N John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 OO N X1 641801.00 0.00 641801.00 0.00 641801.00 N 4.96 IN *Such percentage was calculated based upon an aggregate of 12,938,910 Issuer shares of common stock outstanding as of August 4, 2025 as represented by the Issuer's Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2025. Common Stock, Par Value $0.001 Marker Therapeutics, Inc. 2450 HOLCOMBE BLVD TMC PARTNERS OFFICE 1.311 HOUSTON TX 77021 This Statement on Schedule 13D (this "Schedule") relates to the common stock, par value $0.001 per share ("Common Stock"), of Marker Therapeutics, Inc., a Delaware corporation (the "Issuer"). The principal executive offices of the Issuer are located at 2450 Holcombe Blvd, Suite BCM-A, MS: BCM251 Houston, Texas. This Amendment No. 2 is being filed to report that the beneficial ownership of Common Stock by the Reporting Person has decreased to less than 5% as a result of the sales reported on Schedule A. This Schedule is being filed by John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 (the "Trust"). The Reporting Person's business address is 2100 Old Highway 8 NW, St. Paul, MN 55112. The Reporting Person is a trust. The Reporting Person has not been convicted in a criminal proceeding in the last five years (excluding traffic violations or similar misdemeanors). The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Person is the trustee of the revocable trust which holds the Common Stock. The information set forth in Item 3 of Amendment No. 1 is incorporated herein by reference. The information set forth in Item 4 of Amendment No. 1 is incorporated herein by reference. On the date hereof, the Reporting Person beneficially owns 641,801 shares of Common Stock, which comprises 4.96% of the Common Stock of the Issuer. As of, August 4, 2025, there were 12,938,910 shares of Common Stock of the Issuer issued and outstanding as represented by the Issuer's Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2025. The Reporting Person has the sole power to vote the shares beneficially owned. The transactions effected during the past 60 days by the Reporting Person are set forth on Exhibit A, attached hereto. Only the Reporting Person has the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the shares of Common Stock reported by this statement. Not applicable. John R. Wilson resigned from the Issuer's Board of Directors on January 24, 2025. 1. Schedule A dated as of August 19, 2025. John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 /s/ John R. Wilson John R. Wilson/Trustee 08/20/2025